HELSINKI, October 26, 2015 /PRNewswire/ --
BC Platforms, a world leader in genomic data management solutions, today announced that it has signed a partnership agreement with Helsinki University Hospital to use its genomic management platform to integrate, analyze and interpret their extensive clinical and genealogy data with next-generation sequencing data to provide innovative, personalized treatment options for breast cancer patients at the hospital. As part of the agreement, BC Platforms will use its proprietary cloud-based BC|MERGE platform to carry out all of the core data management tasks including the data integration and interpretation, security and storage to establish a scalable process to utilize increasing amounts of genetic data at the hospital.
The molecular data and clinical patient data will be analyzed in conjunction with a disease predisposition algorithm for Breast Cancer, BOADICEA, developed by the University of Cambridge to enable more holistic clinical decision-making. Whilst the initial application is for cancer research, the platform can be applied widely to other disease areas.
Mr. Mikko Rotonen, Director, ICT Development at Helsinki University Hospital commented: "Helsinki University Hospital is committed to integrating molecular data alongside clinical data to become a leader in translational research in order to provide the best clinical outcomes for our patients. We are pleased to be working with BC Platforms, a leader in genomic software management systems to support us in achieving our vision which has the potential to revolutionize how we make clinical decisions for our patients in the future."
Mr. Tero Silvola, Chief Executive Officer at BC Platforms, commented:
"As the field of next-generation sequencing has exploded there remains an unmet need for this data to be integrated into clinical decision making to provide better treatment options for patients. We are delighted to be collaborating with the Helsinki University Hospital Cancer Center, recognized internationally as leaders in providing innovative personalized treatments to cancer patients with some of the best treatment outcomes."
SOURCE BC Platforms